Mini-pill in lactating women.
A non-comparative study of the progestogen-only oral contraceptive, norgestrel 0.075 mg, in breast-feeding women was conducted at the Centro de Investigaciones Regionales, Merida, Yucatan, Mexico. The study was designed to evaluate the overall acceptability and contraceptive efficacy of norgestrel in breast-feeding women. This report includes a survey of 200 women, all of whom were less than 26 weeks postpartum at admission; 113 were interval patients and 87 were postpartum. Follow-up visits were scheduled at 2, 6 and 12 months after admission. Overall, women experienced an increase in intermenstrual bleeding, amenorrhea, vaginal discharge and breast discomfort. The discontinuation rate at 12 months was 32.5 and the corresponding lost to follow-up rate was 22.5; this is a measure of acceptability. The 12-month life-table rate for pregnancy was 3.4 with a standard error of 2.0. Three women discontinued use of the mini-pill due to accidental pregnancy. One pregnancy was attributed to user failure and the woman conceived 9 months after entering into the study; the other two were attributed to method failure, one woman conceived 3 months after admission and the other conceived 6 months after admission.
Canto
T E
TE
Biology of Reproduction Department, Centro de Investigaciones Regionales, Dr. Hideyo Noguchi, Universidad Autonoma de Yucatan, Merida, Mexico.
Vera
L
L
Polanco
L E
LE
Colven
C E
CE
D000328:Adult; D005193:Family Planning Services; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D009644:Norgestrel / Q000009:adverse effects / Q000494:pharmacology; D011247:Pregnancy
D009644:Norgestrel